Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity.
NAPVSIPQ (NAP), an active fragment of the glial-derived activity-dependent neuroprotective protein, is protective at femtomolar concentrations against a wide array of neural insults and prevents ethanol-induced fetal wastage and growth retardation in mice. NAP also antagonizes ethanol inhibition of L1-mediated cell adhesion (ethanol antagonism). We performed an Ala scanning substitution of NAP to determine the role of ethanol antagonism and neuroprotection in NAP prevention of ethanol embryotoxicity. The Ser-Ile-Pro region of NAP was crucial for both ethanol antagonism and protection of cortical neurons from tetrodotoxin toxicity (neuroprotection). Ala replacement of either Ser-5 or Pro-7 (P7A-NAP) abolished NAP neuroprotection but minimally changed the efficacy of NAP ethanol antagonism. In contrast, Ala replacement of Ile-6 (I6A-NAP) caused a decrease in potency (>2 logarithmic orders) with only a small reduction (<10%) in the efficacy of NAP neuroprotection but markedly reduced the efficacy (50%) and the potency (5 logarithmic orders) of NAP ethanol antagonism. Ethanol significantly reduced the number of paired somites in mouse whole-embryo culture; this effect was prevented significantly by 100 pM NAP or by 100 pM P7A-NAP, but not by 100 pM I6A-NAP. The structure-activity relation for NAP prevention of ethanol embryotoxicity was similar to that for NAP ethanol antagonism and different from that for NAP neuroprotection. These findings support the hypothesis that NAP antagonism of ethanol inhibition of L1 adhesion plays a central role in NAP prevention of ethanol embryotoxicity and highlight the potential importance of ethanol effects on L1 in the pathophysiology of fetal alcohol syndrome.
Wilkemeyer
Michael F
MF
Neurology Service, Veterans Affairs Boston Healthcare System, West Roxbury and Department of Neurology, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
Chen
Shao-yu
SY
Menkari
Carrie E
CE
Brenneman
Douglas E
DE
Sulik
Kathleen K
KK
Charness
Michael E
ME
D000014:Abnormalities, Drug-Induced / Q000196:embryology / Q000517:prevention & control*; D019943:Amino Acid Substitution; D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D004622:Embryo, Mammalian / Q000187:drug effects; D000431:Ethanol / Q000037:antagonists & inhibitors* / Q000633:toxicity; D005260:Female; D018398:Homeodomain Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D016297:Mutagenesis, Site-Directed; D009419:Nerve Tissue Proteins / Q000737:chemistry*; D039842:Neural Cell Adhesion Molecule L1 / Q000037:antagonists & inhibitors; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D009842:Oligopeptides / Q000737:chemistry / Q000494:pharmacology*; D009924:Organ Culture Techniques; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D011247:Pregnancy; D013329:Structure-Activity Relationship; D013779:Tetrodotoxin / Q000633:toxicity
C117632:Adnp protein, mouse; D018398:Homeodomain Proteins; D009419:Nerve Tissue Proteins; D039842:Neural Cell Adhesion Molecule L1; D018696:Neuroprotective Agents; D009842:Oligopeptides; D010446:Peptide Fragments; D000431:Ethanol; D013779:Tetrodotoxin; C425904:davunetide